ifosfamide has been researched along with Cytokine Release Syndrome in 1 studies
Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sang, W | 1 |
| Shi, M | 1 |
| Yang, J | 1 |
| Cao, J | 1 |
| Xu, L | 1 |
| Yan, D | 1 |
| Yao, M | 1 |
| Liu, H | 1 |
| Li, W | 1 |
| Zhang, B | 1 |
| Sun, K | 1 |
| Song, X | 1 |
| Sun, C | 1 |
| Jiao, J | 1 |
| Qin, Y | 1 |
| Sang, T | 1 |
| Ma, Y | 1 |
| Wu, M | 1 |
| Gao, X | 1 |
| Cheng, H | 1 |
| Yan, Z | 1 |
| Li, D | 1 |
| Sun, H | 1 |
| Zhu, F | 1 |
| Wang, Y | 1 |
| Zeng, L | 1 |
| Li, Z | 1 |
| Zheng, J | 1 |
| Xu, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sequential Infusion of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor(CAR) T Cells Against Relapsed and Refractory B-cell Lymphoma[NCT03207178] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ifosfamide and Cytokine Release Syndrome
| Article | Year |
|---|---|
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Topics: Adult; Aged; Anemia; Antigens, CD19; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; CD4-CD8 R | 2020 |